• Epidemiology and Risk Factors
• 23 min
  1. Coronary heart disease epidemiology: global context for a new genetic understanding

  • Prof. Harry Hemingway
• 44 min
  2. Cardiovascular risk factors

  • Dr. Michal Vrablik
• 29 min
  3. Lipid metabolism

  • Dr. Ulrike Beisiegel
• 39 min
  4. Thrombotic risk factors for cardiovascular disease

  • Prof. Gordon Lowe
• Biology of Coronary Heart Disease
• 42 min
  5. Plaque rupture

  • Prof. Petri Kovanen
• 56 min
  6. Transcription factors and complex disease development

  • Dr. Ines Pineda-Torra
• 39 min
  7. Animal models to explore cardiovascular disease

  • Prof. Martin Merkel
• Treatment
• 26 min
  8. Diagnosis and treatment of dyslipidemias

  • Prof. Anton Stalenhoef
• 31 min
  9. Key drug discovery challenges in cardiovascular medicine

  • Dr. Dan Swerdlow
  • Dr. Michael V. Holmes
• Genetics
• 50 min
  10. Moving from GWAS hits to functional variants

  • Prof. Steve Humphries
• 51 min
  11. Heart disease genes and SNPs

  • Prof. Steve Humphries
• 39 min
  12. Familial hypercholesterolaemia: genetic causes and treatment

  • Prof. Steve Humphries
• 22 min
  13. Familial hypercholesterolaemia: cascade testing and monogenic vs. polygenic causes

  • Prof. Steve Humphries
• 28 min
  14. Familial hypercholesterolaemia: case studies, universal screening and novel mutations

  • Prof. Steve Humphries
• 52 min
  15. Genetics of cardiovascular disease

  • Prof. Philippa Talmud
• 35 min
  16. Mendelian randomisation: using genetics to determine causality

  • Dr. Tina Shah
• 33 min
  17. The genetics of abdominal aortic aneurysm

  • Dr. Seamus Harrison
• 49 min
  18. Genome scans for hypertension

  • Prof. Patricia Munroe
• 43 min
  19. Telomeres and cardiovascular disease

  • Dr. Jess Buxton
• 33 min
  20. Translational applications of cardiovascular genomics: opportunities and challenges

  • Dr. Aroon Hingorani
• Archived Lectures *These may not cover the latest advances in the field
• 44 min
  21. Gene-environment interaction and oxidative stress in cardiovascular disease

  • Dr. Jeffrey Stephens
• 34 min
  22. Gene therapy as a therapeutic option for lipoprotein lipase deficiency

  • Dr. Jan Albert Kuivenhoven
• 60 min
  23. Cardiovascular diseases: from epidemiology to nutritional interventions

  • Dr. Antonis Zampelas
• 45 min
  24. Genetic testing for CHD risk: fact or fiction?

  • Prof. Steve Humphries
• 35 min
  25. Pharmacogenetics: progress, pitfalls and clinical potential

  • Prof. Steve Humphries
• 50 min
  26. Familial hyperchlolesterolaemia: a monogenic cause of early CHD

  • Prof. Steve Humphries

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Talk outline
3. What are the conventional risk factors for CHD
4. The multifactorial nature of CAD
5. Gene:environment interaction and risk of CAD
6. Identifying gene:environment interaction
7. The basis for gene:environment interactions
8. Measurement of genetic and environmental factors
9. What is gene environment interaction
10. How to test for gene:environment interaction (1)
11. How to test for gene:environment interaction (2)
12. Prospective vs. case:control studies
13. Candidate gene approach
14. Examples of the candidate gene approach
15. Northwick park heart study II
16. APOE, smoking and CHD risk
17. Role of ApoE and LPL in fat metabolism
18. CHD risk by APOE genotype and smoking
19. Can we replicate these results in another study?
20. APOE E4 effect in smokers and non smokers
21. APOE smoking and CHD risk mechanisms
22. LPL: smoking interaction and CHD risk
23. What is lipoprotein lipase and what does it do?
24. Lipoprotein lipase function 1: hydrolysis
25. Lipoprotein lipase function 2: bridging
26. Common LPL variants
27. Why are raised triglycerides a risk factor?
28. LPL - a good candidate gene
29. D9N, N291S: TG levels and risk of heart disease
30. LPL:smoking interaction on HD risk
31. Survival plot for LPL-D9N and smoking, NPHSII
32. The mechanism for the LPL-D9N effect on risk
33. The LPL-D9 and LPL-N9 bridging function test (1)
34. The LPL-D9 and LPL-N9 bridging function test (2)
35. Can we visualise the binding at 4 degrees?
36. Mechanisms for LPL-N9:smoking interaction
37. Nature and nurture
38. Genome wide association scans
39. Illumina and Affymetix CHIPs
40. Results from the GWASs for CHD
41. SNPSs that have been identified from GWAS
42. Back to where we started
43. Conclusion

Topics Covered

• Conventional CVHD risk factors
• Multifactorial nature of CVD
• Gene-environment interaction and how to test for it
• Candidate gene approach to CVD genetics vs. genome-wide scans
• Examples of the candidate gene approach and gene-environment interaction, APOE and smoking interaction, LPL and smoking
• Mechanisms for these effects
• Novel genes identified by genome-wide scans for CHD and lipid traits

Links

Series:

• Genetics of Cardiovascular Disease

Categories:

• Clinical Practice
• Genetics & Epigenetics

Therapeutic Areas:

• Cardiovascular & Metabolic

Talk Citation

Publication History

• Published on November 24, 2008

Financial Disclosures

• Prof. Philippa Talmud has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.